- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00987246
Study on the Efficacy of LAS41005 in the Treatment of Actinic Keratosis
July 27, 2015 updated by: Almirall, S.A.
Study on the Efficacy of LAS41005 Compared to Placebo and to LAS106521 in the Treatment of Actinic Keratosis Grade I to II
The purpose of this study is to investigate the efficacy of LAS41005 in comparison to placebo and to LAS106521 in actinic keratosis (AK).
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
To investigate as primary objective:
- Superiority to placebo and non-inferiority to LAS106521 measured by histological clearance of one predefined target lesion;
To investigate as secondary objective:
- Superiority to LAS106521
- Improvement of treated lesions (lesion response)
- Assessment of tolerability and safety by physicians global assessment score (PGA, PGT)
- Patient's assessment of tolerability and efficacy and patient's compliance
Study Type
Interventional
Enrollment (Actual)
470
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Altenkirchen, Germany, 57610
- Almirall Facility Site#37
-
Augsburg, Germany, 86163
- Almirall Facility Site#24
-
Augsburg, Germany, 86179
- Almirall Facility Site#23
-
Berlin, Germany, 10117
- Almirall Facility Site#01
-
Berlin, Germany, 10437
- Almirall Facility Site#28
-
Berlin, Germany, 10827
- Almirall Facility Site#02
-
Berlin, Germany, 10967
- Almirall Facility Site#34
-
Berlin, Germany, 12353
- Almirall Facility Site#35
-
Bonn, Germany, 53111
- Almirall Facility Site#31
-
Buxtehude, Germany, 21614
- Almirall Facility Site#04
-
Detmold, Germany, 32756
- Almirall Facility Site#40
-
Dresden, Germany, 01097
- Almirall Facility Site#30
-
Dülmen, Germany, 48249
- Almirall Facility Site#11
-
Düsseldorf, Germany, 40225
- Almirall Facility Site#12
-
Frankfurt, Germany, 60590
- Almirall Facility Site#17
-
Freiburg, Germany, 79104
- Almirall Facility Site#22
-
Friedrichshafen, Germany, 88045
- Almirall Facility Site#36
-
Fulda, Germany, 36037
- Almirall Facility Site#19
-
Göttingen, Germany, 37075
- Almirall Facility Site#32
-
Hamburg, Germany, 20148
- Almirall Facility Site#09
-
Jena, Germany, 07740
- Almirall Facility Site#29
-
Kiel, Germany, 24103
- Almirall Facility Site#07
-
Kiel, Germany, 24105
- Almirall Facility Site#08
-
Koblenz, Germany, 56068
- Almirall Facility Site#15
-
Landau, Germany, 76829
- Almirall Facility Site#21
-
Leipzig, Germany, 04103
- Almirall Facility Site#27
-
Lübeck, Germany, 23538
- Almirall Facility Site#06
-
Mahlow, Germany, 15831
- Almirall Facility Site#03
-
München, Germany, 80337
- Almirall Facility Site#25
-
München, Germany, 81476
- Almirall Facility Site#39
-
Nördlingen, Germany, 86720
- Almirall Facility Site#33
-
Osnabrück, Germany, 49078
- Almirall Facility Site#38
-
Pinneberg, Germany, 25421
- Almirall Facility Site#05
-
Quedlinburg, Germany, 06484
- Almirall Facility Site#26
-
Radolfzell, Germany, 78315
- Almirall Facility Site#20
-
Salzwedel, Germany, 29410
- Almirall Facility Site#10
-
Soest, Germany, 59494
- Almirall Facility Site#16
-
Vechta, Germany, 49377
- Almirall Facility Site#14
-
Wiesbaden, Germany, 65191
- Almirall Facility Site#18
-
Wuppertal, Germany, 42275
- Almirall Facility Site#13
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 85 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Main Inclusion Criteria:
- Have at least 4 but not more than 10 clinically confirmed AK target lesions of mild to moderate intensity within the face/forehead or bald scalp (excluding eyelids, lips, and mucosa), i.e. actinic keratosis grade I and II according to Olsen EA et al. 1991
- Woman of childbearing potential are allowed to participate in this study only if they use a highly effective method of contraception
Main Exclusion Criteria:
- Have received effective treatment of AK in the three months preceding this clinical trial
- Have known hypersensitivity to LAS41005 or LAS106521
- Have currently other malignant or benign tumors of the skin within the treatment area (e.g. malignant melanoma, basal cell carcinoma, squamous cell carcinoma)
- Patient's taking phenytoin
- Show cornu cutaneum like alterations of the skin in the face or the bald scalp (target area)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: QUADRUPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
PLACEBO_COMPARATOR: Placebo
|
Topical
|
|
EXPERIMENTAL: LAS41005
|
Topical
|
|
ACTIVE_COMPARATOR: LAS106521
|
Topical
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Histological status of AK target lesion
Time Frame: Day 140
|
Day 140
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Estrella Garcia, MD, MBA, Almirall Hermal GmbH
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2008
Primary Completion (ACTUAL)
June 1, 2009
Study Completion (ACTUAL)
June 1, 2009
Study Registration Dates
First Submitted
September 29, 2009
First Submitted That Met QC Criteria
September 29, 2009
First Posted (ESTIMATE)
September 30, 2009
Study Record Updates
Last Update Posted (ESTIMATE)
July 28, 2015
Last Update Submitted That Met QC Criteria
July 27, 2015
Last Verified
July 1, 2015
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- H 1005 6002 - 0702
- EudraCT: 2007-003889-18
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.